NCT07065682 Effetivity of Dutasteride and Aloe Vera Extract Combination on Angiogenesis and Obstruction on Benign Prostatic Hyperplasia
| NCT ID | NCT07065682 |
| Status | Recruiting |
| Phase | Phase 1 |
| Sponsor | Universitas Diponegoro |
| Condition | BPH (Benign Prostatic Hyperplasia) |
| Study Type | INTERVENTIONAL |
| Enrollment | 84 participants |
| Start Date | 2023-07-01 |
| Primary Completion | 2024-12-01 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
Phase 1 is the earliest stage of human testing — safety and dosage are the primary focus. Visits are frequent and medical supervision is intensive. You will be among the first people to receive this treatment.
This trial targets 84 participants in total. It began in 2023-07-01 with a primary completion date of 2024-12-01.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
This study is a double blinded RCT with pre-post test design on the effect of combination of dutasteride and aloe vera, compared to dutasteride only, on uroflowmetry results, prostate volume, and VEGF serum level among patients with benign prostate hyperplasia. The treatment was given for 12 weeks
Eligibility Criteria
Inclusion Criteria: * Diagnosed with BPH clinically or radiologically (prostate volume \> 30 gram, Qmax \<15 mL/s) * Willing to participate to the study Exclusion Criteria: * Clinically or radiologically suspected of having prostatic cancer * Previous prostatic surgery * Patients with urinary retention * Patients with BPH complications: urinary tract infections, urolithiasis, or hydroneprhosis * Previously consumed alpha blocker or 5ARI in the last 6 months * Have consumed aloe vera extract routinely
Contact & Investigator
Achmad Rizky Herda Pratama dr. Achmad Rizky Herda Pratama, Sp.U, S.H, Urologist
✉ herdapratama@gmail.com📞 +6282184801976
Frequently Asked Questions
Who can join the NCT07065682 clinical trial?
This trial is open to male participants only, aged 50 Years or older, studying BPH (Benign Prostatic Hyperplasia). Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
What phase is the NCT07065682 trial and what does that mean for participants?
Phase 1 trials are the first stage of human testing. The primary goal is to assess safety and determine appropriate dosage levels. Participants are closely monitored. These trials typically involve a small number of volunteers.
Is NCT07065682 currently recruiting?
Yes, NCT07065682 is actively recruiting participants. Contact the research team at herdapratama@gmail.com for enrollment information.
Where is the NCT07065682 trial being conducted?
This trial is being conducted at Karawang, Indonesia.
Who is sponsoring the NCT07065682 clinical trial?
NCT07065682 is sponsored by Universitas Diponegoro. The trial plans to enroll 84 participants.